Abstract
Introduction. The microflora of the body is a complex ecological community, clearly distributed at its levels in the human digestive tract. With the development of the pathology of the digestive system, conditions are created for the translocation of bacteria to unusual locus of habitat. Treatment and prevention of cardiovascular disease involves the use of drugs that have a damaging effect on the mucous membrane of the gastrointestinal tract. In order to reduce aggression, drugs that suppress acid production are used, the prolonged use of which is one of the main causes of impaired microbiocenosis of the small intestine. This is the basis for the formation of functional disorders, the appearance of clinical manifestations that worsen the quality of life of patients.
Material and methods. We examined 30 patients with cardiovascular pathology who had been taking acetylsalicylic acid drugs for a long time in combination with proton pump inhibitors (PPI) and having non-specific complaints. To confirm the bacterial overgrowth syndrome, all patients underwent a hydrogen breath test.
Results. In 17 (56.6%) patients, an increase in the gradient of hydrogen in exhaled air was detected.
Conclusion. Prolonged use of PPI in order to minimize the negative effects of antiplatelet therapy can lead to bacterial overgrowth syndrome, which has pronounced clinical symptoms, which reduces the patient's quality of life.
References
- Buza V.V., Karpov Yu.A., Samko A.N., Levitskiy I.V., Lopukhova V.V. Long-term results of coronary stenting: role of antiplatelet therapy. Russkiy Meditsinskiy Zhurnal – Kardiologiya (Russian Medical Journal – Cardiology). 2008; 16 (21): 1604–7 (in Russ.).
- Vorobyeva N.M., Dobrovolskiy A.B., Titayeva E.V., Panchenko E.P. Thromboembolic complications and the diagnostic significance of D-dimer in cardiovascular diseases: a retrospective study of 1000 patients. Kardiologicheskiy Vestnik (Cardiological Bulletin). 2011; 2: 10–5 (in Russ.).
- Kaminnyy A.I. Therapy with antiplatelet agents and non-steroidal anti-inflammatory drugs. Risk to benefit ratio. Lechashchiy Vrach (Attending Physician). 2009; 7: 1–6 (in Russ.).
- Ardatskaya M.D. Small intestinal bacterial overgrowth syndrome and impaired digestion and absorption. Poliklinika (Clinic). 2009; 2: 38–40 (in Russ.).
- Bondarenko V.M., Matsulevich T.V. Intestinal dysbiosis as a clinical-laboratory syndrome: current state of the problem. Guide for doctors. Moscow: GEOTAR-Media; 2007 (in Russ.).
- Minushkin O.N., Maslovskiy L.V., Topchiy T.B., Skibina Yu.S., Evsikov A.E. Approaches to the treatment of patients with the syndrome of excessive bacterial growth in the small intestine, which developed in connection with the pathology of the upper gastrointestinal tract. Lechashchiy Vrach (Attending Physician). 2017; 2: 40–4 (in Russ.).
- Nemtsov L.M. Excessive bacterial growth syndrome: current issues of diagnosis and management. Vestnik Vitebskogo Gosudarstvennogo Meditsinskogo Universiteta (Bulletin of Vitebsk State Medical University).2015; 14 (2): 15–20 (in Russ.).
- Khapayev B.A., Zhuravleva M.V., Rebrov V.G Undesirable effects of proton pump blockers and H2 blockers-histamine receptors. Molecular mechanisms ofundesirable effects of drugs. Moscow: Russian Doctor; 2005 (in Russ.).
- Plotnikova E.Yu., Zakharova Yu.V. Diagnosis and treatment of excess bacterial growth syndrome. Russkiy Meditsinskiy Zhurnal (Russian Medical Journal). 2015; 13: 767 (in Russ.).
- Krajicek E.J., Hansel S.L., Small intestinal bacterial overgrowth. Mayo Clin. Proc. 2016; 91 (12): 1828–33. DOI: 10.1016/j.mayocp.2016.07.025
- Lombardo L., Foti M., Ruggia O., Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 2010; 8 (6): 504–8. DOI: 10.1016/j.cgh.2009.12.022
- Zhong C., Qu C., Wang B., Liang S., Zeng B. Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. J. Clin. Gastroenterol. 2017; 51 (4): 300. DOI: 10.1097/MCG.0000000000000814
About the authors
- Nikita S. Nazarov, Cand. Med. Sc., Researcher, orcid.org/0000-0003-3278-7605
- Vladimir A. Loginov, Cand. Med. Sc., Gastroenterologist, orcid.org/0000-0001-7176-4022
